CAR-T Cell Therapy: Advances in Kidney-Related Diseases
Abstract: Background: Chimeric antigen receptor (CAR)-T cell therapy represents a significant advancement in the field of immunotherapy, providing targeted eradication of abnormal cells through the recognition between CAR and target antigens. This approach has garnered considerable attention due to its promising results in the clinical treatment of hematological malignancies and autoimmune diseases. As the focus shifts toward exploring novel targets and expanding the application of CAR-T cell therapy to solid tumors, including renal malignancies, researchers are pushing the boundaries of this innovative treatment. However, it is crucial to address the observed comorbidities associated with CAR-T cell therapy, particularly nephrotoxicity, due to the superseding release of cytokines and impairment of normal tissue. Summary: Our review discusses the research strategies and nephrotoxicity related to CAR-T cell therapy in various kidney-related diseases and provides insights into enhancing investigation and optimization. Key Messages: CAR-T cell therapy has captured the attention of researchers and clinicians in the treatment of renal malignancies, multiple myeloma, systemic lupus erythematosus, and acquired immunodeficiency syndrome, which may lead to potential nephrotoxicity as they involve primary or secondary kidney complications. Understanding and summarizing the current research progress of CAR-T cell therapies can provide valuable insights into novel targets and combinations to optimize research models and enhance their clinical value.
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
CAR-T Cell Therapy: Advances in Kidney-Related Diseases ; volume:10 ; number:2 ; year:2024 ; pages:143-152 ; extent:10
Kidney diseases ; 10, Heft 2 (2024), 143-152 (gesamt 10)
- Urheber
-
Wu, Longyuan
Feng, Youqin
Huang, Yue
Feng, Jingjing
Hu, Yongxian
Huang, He
- DOI
-
10.1159/000536194
- URN
-
urn:nbn:de:101:1-2405020105326.022753353279
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:53 MESZ
Datenpartner
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Wu, Longyuan
- Feng, Youqin
- Huang, Yue
- Feng, Jingjing
- Hu, Yongxian
- Huang, He
Ähnliche Objekte (12)
Rewiring mitochondrial metabolism to counteract exhaustion of CAR-T cells
Chimeric antigen receptor‐engineered adoptive cell therapy for AML: Current status and future perspectives
Special issue: CAR‐T cell therapy for hematological malignancies
HLA‐matched allogeneic anti‐CD19 CAR‐T therapy in treating a relapsed/refractory acute lymphoblastic leukemia patient with high tumor burden
Does A Child Quantity-Quality Trade-Off Exist? Evidence from the One-Child Policy in China
Unraveling the roles and mechanisms of mitochondrial translation in normal and malignant hematopoiesis
Non‐BCMA targeted CAR‐T cell therapies for multiple myeloma
Family Size and Children’s Education: Evidence from the One-Child Policy in China
Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO Congress
Job Satisfaction and Trade Union Membership in Germany
Suffering and prejudice: Do negative emotions predict immigration concerns?
Immigration and Crimes against Natives: The 2015 Refugee Crisis in Germany
Rewiring mitochondrial metabolism to counteract exhaustion of CAR-T cells
Chimeric antigen receptor‐engineered adoptive cell therapy for AML: Current status and future perspectives
Special issue: CAR‐T cell therapy for hematological malignancies
HLA‐matched allogeneic anti‐CD19 CAR‐T therapy in treating a relapsed/refractory acute lymphoblastic leukemia patient with high tumor burden
Does A Child Quantity-Quality Trade-Off Exist? Evidence from the One-Child Policy in China
Unraveling the roles and mechanisms of mitochondrial translation in normal and malignant hematopoiesis
Non‐BCMA targeted CAR‐T cell therapies for multiple myeloma
Family Size and Children’s Education: Evidence from the One-Child Policy in China
Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO Congress
Job Satisfaction and Trade Union Membership in Germany
Suffering and prejudice: Do negative emotions predict immigration concerns?
Immigration and Crimes against Natives: The 2015 Refugee Crisis in Germany
Rewiring mitochondrial metabolism to counteract exhaustion of CAR-T cells
Chimeric antigen receptor‐engineered adoptive cell therapy for AML: Current status and future perspectives
Special issue: CAR‐T cell therapy for hematological malignancies
HLA‐matched allogeneic anti‐CD19 CAR‐T therapy in treating a relapsed/refractory acute lymphoblastic leukemia patient with high tumor burden
Does A Child Quantity-Quality Trade-Off Exist? Evidence from the One-Child Policy in China
Unraveling the roles and mechanisms of mitochondrial translation in normal and malignant hematopoiesis
Non‐BCMA targeted CAR‐T cell therapies for multiple myeloma
Family Size and Children’s Education: Evidence from the One-Child Policy in China
Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO Congress
Job Satisfaction and Trade Union Membership in Germany
Suffering and prejudice: Do negative emotions predict immigration concerns?